HK Stock Market Move | INNOCARE (09969) rose nearly 4%, and the first subject in the Phase III registration clinical trial of ICP-332 for the treatment of atopic dermatitis was dosed.

INNOCARE (09969) rose nearly 4%, as of the time of publication, it had risen by 3.66% to HK$6.47, with a turnover of HK$6.6765 million. On the news front, on November 15, INNOCARE announced on its official WeChat public account that the Phase III registration clinical trial of its independently developed novel TYK2 inhibitor ICP-332 for the treatment of atopic dermatitis (AD) had completed the first dosing of subjects in China. ICP-332 is a type 1 innovative drug with global independent intellectual property rights owned by INNOCARE. It is a potent, highly selective novel oral TYK2 inhibitor developed for the treatment of various T-cell-related autoimmune diseases, including atopic dermatitis, vitiligo, and inflammatory bowel disease. Caitong believes that the company is actively laying out in the field of self-immunity, as ICP-332 has now entered Phase III clinical trials. In Phase II clinical trials, ICP-332 showed better-than-expected efficacy and may become the best product in its class.